| Literature DB >> 24587796 |
Abstract
Background. Nested variant of urothelial carcinoma was added to the WHO's classification in 2004. Aims. To review the literature on nested variant of urothelial carcinoma. Results. About 200 cases of the tumour have been reported so far and it has the ensuing morphological features: large numbers of small confluent irregular nests of bland-appearing, closely packed, haphazardly arranged, and poorly defined urothelial cells infiltrating the lamina propria and the muscularis propria. The tumour has a bland histomorphologic appearance, has an aggressive biological behaviour, and has at times been misdiagnosed as a benign lesion which had led to a significant delay in the establishment of the correct diagnosis and contributing to the advanced stage of the disease. Immunohistochemically, the tumour shares some characteristic features with high-risk conventional urothelial carcinomas such as high proliferation index and loss of p27 expression. However, p53, bcl-2, or EGF-r immunoreactivity is not frequently seen. The tumour must be differentiated from a number of proliferative lesions of the urothelium. Conclusions. Correct and early diagnosis of this tumour is essential to provide early curative treatment to avoid diagnosis at an advanced stage. A multicentre trial is required to identify treatment options that would improve the outcome of this tumour.Entities:
Year: 2014 PMID: 24587796 PMCID: PMC3920611 DOI: 10.1155/2014/192720
Source DB: PubMed Journal: Adv Urol ISSN: 1687-6369
A list of some of the reported cases of nested variant of urothelial carcinoma and their outcome.
| Patient | Reference | Age/sex | Pathologic stage | AJCC stage | Treatment | Status | Follow-up | Associated CUC (WHO/ISUP 1998) |
|---|---|---|---|---|---|---|---|---|
| 1 | Lin et al. [ | 90/F | pT1 | 1 | Cystectomy | NED | 30 | No |
|
| ||||||||
| 2 | Lin et al. [ | 73/F | pT3b | III | Cystectomy + chemotherapy | NED | 5 | No |
|
| ||||||||
| 3 | Lin et al. [ | 65/M | pT2b | IV | Cystectomy + chemotherapy | AWM | 16 | Flat CIS |
|
| ||||||||
| 4 | Lin et al. [ | 70/M | pT3b | III | Cystectomy + chemotherapy | AWM | 15 | Flat CIS |
|
| ||||||||
| 5 | Lin et al. [ | 61/M | pT3b | IV | Cystectomy + chemotherapy | NED | 19 | Flat CIS |
|
| ||||||||
| 6 | Lin et al. [ | 80/M | pT3b | III | Cystectomy | NED | 27 | Flat CIS |
|
| ||||||||
| 7 | Lin et al. [ | 66/M | pT1 | I | Cystectomy | NED | 22 | No |
|
| ||||||||
| 8 | Lin et al. [ | 53/M | pT1 | I | Cystectomy | NED | 19 | No |
|
| ||||||||
| 9 | Lin et al. [ | 51/M | pT2 | IV | Radiotherapy | DOD | 3 | No |
|
| ||||||||
| 10 | Lin et al. [ | 59/M | pT2a | II | Cystectomy | NED | 24 | No |
|
| ||||||||
| 11 | Lin et al. [ | 42/F | pT2a | II | Cystectomy | NED | 20 | No |
|
| ||||||||
| 12 | Lin et al. [ | 75/M | pT2a | I | TUR | NED | 12 | Low-grade papillary UC |
|
| ||||||||
| 13 | Wang et al. [ | 49/F | G3pT4M1 | Partial cystectomy; en bloc resection of distal ileum, caecum; resection of transplanted pancreas; right salpingo-oophorectomy; repair of ileocolostomy anastomosis; chemotherapy | DOD | 12 months | Plus conventional high-grade TCC | |
|
| ||||||||
| 14 | Tatsura et al. [ | 70/M | G3pT3b Nx M0 | >III | Bladder adherent and cystectomy abandoned; open bladder total layer biopsy + bilateral ureterocutaneostomy; chemotherapy | Alive with disease | 12 months | Small tumour atypical cells positive for cytokeratin |
|
| ||||||||
| 15 | Terada [ | 80/F | pT1 | TUR | Alive with no tumour | 6 months | Atypical cells forming nests and tubules in lamina propria without surface urothelial involvement | |
|
| ||||||||
| 16 |
Terada [ | 78/M | pT1 | TUR | Alive with no tumour | 15 months | Atypical cells forming nests and tubules in lamina propria without surface urothelial involvement | |
|
| ||||||||
| 17 | De Berardinis et al. [ | 70/M | pT2aN+ | TUR twice + BCG for initial conventional G3pT1b tumour and cystectomy + lymphadenectomy + chemotherapy for nested variant was started | Alive 12 months after initial diagnosis of conventional urothelial carcinoma | 12 months after initial diagnosis and exact duration of follow-up after cystectomy not stated but patient just started on chemotherapy after cystectomy | ||
|
| ||||||||
| 18, 19, 20, 21, 22, 23, 24 | Cardillo et al. [ | 5 M | 3 stage 1; | 6 patients with stages I to III tumours underwent cystectomy; | Follow-up outcome data not provided | Follow-up outcome data not provided in paper | ||
|
| ||||||||
| 25 | Dundar et al. [ | 78/M | pT4N1 | Cystoprostatectomy and chemotherapy planned but not given at time of publication | Alive | Follow-up data not available at time of publication | ||
|
| ||||||||
| 26 | Dundar et al. [ | 56/M | pT2 at least | TURBT he refused radical cystoprostatectomy | Alive but had 3 recurrences of nested variant urothelial carcinoma resected over 23 months | 23 months | ||
|
| ||||||||
| 27 | Badoual et al. [ | Details not available | Details not available in English | Details not available | Details not available to author | Details not available | Details not available | Details not available |
|
| ||||||||
| 28 | Badoual et al. [ | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available |
|
| ||||||||
| 29 | Krishnamoorthy et al. [ | 45 F | pT1 | TUR | Alive | No follow-up paper soon after TUR | ||
|
| ||||||||
| 30 | Ozdemir et al. [ | 65 M | pT2 at least | TUR biopsy | Alive no data provided on follow-up case reported after biopsy | Data not available | ||
|
| ||||||||
| 31 |
Holmäng and Johansson 2001 [ | 10 patients | Details not available to author | Details not available to author | 7 died of disease or treatment complications (4 months–40 months); 1 died of unrelated cause after 90 months; follow-up ≤1 year for the remaining 2 | |||
|
| ||||||||
| 32 | Ooi et al. [ | 74/M | Bladder tumour with ureteric involvement | TUR + bilateral local resection of ureter and chemotherapy | Alive with tumour (partial response) | 12 months | ||
|
| ||||||||
| 33–86 | Linder et al. [ | 52 patients | 36 (69%) with pT3-T4 | All had radical cystectomy | Analysis in the comparison of patients with nested variant matched with a cohort of conventional urothelial carcinoma showed no significant differences in the 10-year local recurrence free survival (83% versus 80%, | Median follow-up 10.8 months | ||
|
| ||||||||
| 87 | Tripodi et al. [ | 49/F | Renal pelvis pT1 | Nephrectomy and upper ureterectomy | Alive | No long-term follow-up at time of publication | ||
|
| ||||||||
| 88 | Cerda et al. [ | 53/M | pT3b pN1 | TUR and radical cystoprostatectomy, radiotherapy, and chemotherapy | Died due to advanced metastatic disease | 12 months | ||
|
| ||||||||
| 89 | Cerda et al. [ | 83/F | pT2 | TUR (surgical procedure not done due to advanced age) | Died of disease | 3 years (36 months) | ||
|
| ||||||||
| 90 |
Yildiz et al. [ | 60/M | T2 at least (muscle invasion) | TUR further details in Turkish language | Not found in data | |||
|
| ||||||||
| 91 |
Pusztaszeri et al. [ | Renal pelvis and ureter | Details not available to author | Details not available to author | Details not available to author | |||
|
| ||||||||
| 92 | Lau [ | Renal pelvis | Locally advanced | Details not available to author | Details not available to author | Details not available to author | ||
|
| ||||||||
| 93 | Stern [ | 45/M | Details not available to author | Details not available to author | TUR | Alive tumour recurred 18 months later | 18 months | |
|
| ||||||||
| 94, 95, 96 | Talbert and Young [ | 3 men | Details not available to author | Details not available to author | Details not available to author | |||
|
| ||||||||
| 97, 98, 99, 100 | Murphy and Deana [ | 4 cases | Details not available to author | Details not available to author | Details not available to author | Tumours persisted/recurred | Details not available to author | |
|
| ||||||||
| 101–130 | Wasco et al. [ | 30 cases | All but 1 invasive tumours (9% pT1; pT2-3a; 65% pT3b; 17% pT4) | All had cystectomy and 15 had cystectomy and chemotherapy | 3 (10%) died of disease; 16 (55%) alive with persistent or recurrent disease; 10 (34%) alive without disease | Follow-up in 29 patients (97%) with median 12 months (range 1–31 months) | Focal atypia in 90% and focal high-grade cytological atypia at tumour base in 40% | |
|
| ||||||||
| 131–134 | Young and Oliva [ | 4 patients | Details not available to author | Details not available to author | Details not available to author | 1 or more specimens were misinterpreted as benign | ||
|
| ||||||||
| 135–150 | Drew et al. [ | 16 cases with marked male predominance | Details not available to author | Details not available to author | 3 with no disease | Average follow-up 16.6 months | A few cells in every case with cytological atypia | |
|
| ||||||||
| 151 and | Xiao et al. [ | 69/M | pT4 N1 | Radical cystoprostatectomy and chemotherapy | Developed bone and soft tissue metastases in 4 months | 4 months | Focal urothelial CIS and multiple foci of urothelial atypia | |
|
| ||||||||
| 153 | Huang et al. [ | 83/M | G3pT2-3 | Cystoprostatectomy | Alive no long-term follow-up data available to author | |||
|
| ||||||||
| 154–164 | Volmar et al. [ | 11 patients | 5 pT2-3 N0 | Details not available to author | Details not available | |||
|
| ||||||||
| 165–174 |
Holmäng and Johansson [ | 10 patients | Details not available | Locoregional therapy | 7 died of disease or treatment complications 4–40 months after diagnosis; | |||
|
| ||||||||
| 175–177 | Liedberg et al. [ | 3 patients | Advanced muscle-invasive 2 with lymph node involvement | Final outcome not available | ||||
|
| ||||||||
| 178–200 | Cox and Epstein [ | 23 cases | 20 T2-T3 | 18 had TURBT | 3 of 17 patients developed metastasis 2 lung 1 unknown with 2 of the 3 dead of disease; 1 patient died of disease with no known details | Follow-up for 17 patients | ||
Abbreviations: M: male; F: female; NED: alive with no evidence of disease; AWM: alive with metastasis; DOD: dead of disease; CIS: carcinoma in situ; CUC: conventional urothelial carcinoma; TUR: transurethral resection of tumour; and Lin et al.: Lin O, Cardillo M, Dalbagni G, Linkov I, Hutchinson B, and Reuter V E. Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 12 cases. Modern Pathology 2003; 16(12): 1289-1298.
Nested variant of urothelial carcinoma: example of results and geographic distribution of several markers in nested variant of urothelial carcinoma taken from Lin O, Cardillo M, Dalbagni G, Linkov I, Hutchinson B, and Reuter V E. Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 12 cases. Modern Pathology 2003; 16(12): 1289–1298.
| Case | Ref. | P21 result | P21 location | P27 result | P27 location | P53 result | P53 location | EGF-R result | Bc12 result | Bc12 location | MIB-1% | MIB1 location | Other comments |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Lin et al. [ | + | Diffuse | + | Surface | − | − | − | 20 | Diffuse | |||
|
| |||||||||||||
| 2 | Lin et al. [ | + | Diffuse | + | Diffuse | − | − | − | 15 | Diffuse | |||
|
| |||||||||||||
| 3 | Lin et al. [ | + | Diffuse | − | − | − | − | 35 | Diffuse | ||||
|
| |||||||||||||
| 4 | Lin et al.[ | + | Diffuse | + | Surface | − | − | − | 35 | Diffuse | |||
|
| |||||||||||||
| 5 | Lin et al. [ | + | Base | + | Surface | + | Base | − | + | Surface | 2 | Base | |
|
| |||||||||||||
| 6 | Lin et al. [ | − | + | Surface | − | − | − | 20 | Diffuse | ||||
|
| |||||||||||||
| 7 | Lin et al. [ | + | Base | + | Surface | − | − | + | Surface | 35 | Diffuse | ||
|
| |||||||||||||
| 8 | Lin et al. [ | + | Base | + | Surface | − | − | − | 15 | Base | |||
|
| |||||||||||||
| 9 | Lin et al. [ | − | + | Surface | + | Diffuse | − | − | 30 | Diffuse | |||
|
| |||||||||||||
| 10 | Lin et al. [ | + | Diffuse | + | Surface | − | − | − | 30 | Base | |||
|
| |||||||||||||
| 11 | Lin et al. [ | + | Base | + | Surface | − | − | − | 20 | Diffuse | |||
|
| |||||||||||||
| 12 | Lin et al. [ | + | Base | + | Surface | + | Base | − | − | 15 | Base | ||
|
| |||||||||||||
| 13 | Wang et al. [ | Not done | Not done | − | Not done | Not done | Not done | ||||||
|
| |||||||||||||
| 14 | Tatsura et al. [ | Not done | Not done | Not done | Not done | Not done | Not done | Cytokeratin+ | |||||
|
| |||||||||||||
| 15 | Terada [ | Not done | + | Not done | Ki-67 labeling = 15%; +cytokeratins; +EMA; | ||||||||
|
| |||||||||||||
| 16 | Terada [ | Not done | Not done | + | Not done | Ki-67 labeling = 30%; +cytokeratins; +EMA, +p63, +p53, +C10, +CEA, +MUC1 | |||||||
|
| |||||||||||||
| 17 | De Berardinis et al. [ | Not done | Not done | Strongly+ | Not done | Ki-67 +high expression | |||||||
|
| |||||||||||||
| 18, 19, 20, 21, 22, 23, 24 | Cardillo et al. [ | Not done | Not done | Not done | Not done | ||||||||
|
| |||||||||||||
| 25 | Dundar et al. [ | Not done | +40% | +40% | Not done | Ki-67 20%; 34 | |||||||
|
| |||||||||||||
| 26 | Dundar et al. [ | Not done | +50% | +40% | Ki-67 15%; +34 | ||||||||
|
| |||||||||||||
| 27 | Badoual et al. [ | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available |
|
| |||||||||||||
| 28 | Badoual et al. [ | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available |
|
| |||||||||||||
| 29 | Krishnamoorthy et al. [ | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Details not available | Irregular nests of tubules in lamina propria |
|
| |||||||||||||
| 30. | Ozdemir et al. [ | Not done | Not done | Not done | Not done | Not done | Details not available to author | ||||||
|
| |||||||||||||
| 31 |
Holmäng and Johansson [ | Details not available to author | Deatials not available to author | Deatials not available to author | Deatials not available to author | Deatials not available to author | Deatials not available to author | Deatials not available to author | Deatials not available to author | Deatials not available to author | Deatials not available to author | Deatials not available to author | |
|
| |||||||||||||
| 32 | Ooi et al. [ | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | |
|
| |||||||||||||
| 33 to 86 | Linder et al. [ | 52 patients | Details not availabe | Details not availabe | Details not availabe | Details not availabe | Details not availabe | Details not availabe | Details not availabe | Details not availabe | Details not availabe | Details not availabe | |
|
| |||||||||||||
| 87 | Tripodi et al. [ | Not done | Not done | Not done | +P63 | ||||||||
|
| |||||||||||||
| 88 | Cerda et al. [ | Not done | Not done | Not done | Not done | Not done | Not done | Not done | Not done | +CK7,+CK20, | |||
|
| |||||||||||||
| 89 | Cerda et al. [ | Not done | Not done | Not done | Not done | Not done | Not done | Not done | Not done | Not done | Not done | +CK7,+CK20, +34 | |
|
| |||||||||||||
| 90 |
Yildiz et al. [ | Details unavailable | Details unavailable | Details unavailable | Details unavailable | Details unavailable | Details unavailable | ||||||
|
| |||||||||||||
| 91 |
Pusztaszeri et al. [ | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | |||||
|
| |||||||||||||
| 92 | Lau [ | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | |
|
| |||||||||||||
| 93 | Stern [ | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | |
|
| |||||||||||||
| 94–96 | Talbert and Young [ | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | |
|
| |||||||||||||
| 97–100 | Murphy and Deana [ | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | |
|
| |||||||||||||
| 101–130 | Wasco et al. [ | CK7+ (93%); CK20+ (68%); P63+ (92%); CK903+ (92%) | |||||||||||
|
| |||||||||||||
| 131–134 | Young and Oliva [ | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | |
|
| |||||||||||||
| 135–150 | Drew et al. [ | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | |
|
| |||||||||||||
| 151 and 152 | Xiao et al. [ | High +p53 | Both Strongly+ for 63; | ||||||||||
|
| |||||||||||||
| 153 | Huang et al. [ | +CK7; | |||||||||||
|
| |||||||||||||
| 154–164 | Volmar et al. [ | 8.8% | +p53 4.2%; | ||||||||||
|
| |||||||||||||
| 165–174 |
Holmäng and Johansson [ | Details not available | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | |
|
| |||||||||||||
| 175–177 | Liedberg et al. [ | Details not available | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | |
|
| |||||||||||||
| 178–200 | Cox and Epstein [ | Details not available | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | Details not available to author | |
Figure 1Low-power view showing closely packed, irregularly spaced, glandular, and cystic urothelial nests somewhat resembling von Brunn nests. Note that the overlying urothelium appears uninvolved (hematoxylin-eosin, original magnification ×100). Nested variant of urothelial carcinoma taken from Dhall et al. [2]. The figures have been reproduced with the permission of the editor in chief of Archives of Pathology and Laboratory Medicine on behalf of the editorial board of the journal.
Figure 2Low-power view showing bland tumor cells in the nested pattern infiltrating the muscularis propria (hematoxylin-eosin, original magnification ×100). Nested variant of urothelial carcinoma taken from Dhall et al. [2]. The figures have been reproduced with the permission of the editor in chief of Archives of Pathology and Laboratory Medicine on behalf of the editorial board of the journal.
Figure 3On high-power view, the tumour cells show no significant cytologic atypia (hematoxylin-eosin, original magnification ×400). Nested variant of urothelial carcinoma taken from Dhall et al. [2]. The figures have been reproduced with the permission of the editor in chief of Archives of Pathology and Laboratory Medicine on behalf of the editorial board of the journal.
Figure 5Gross photo of Case 1 shows an edematous urinary bladder mucosa and markedly and diffusely thickened bladder wall Xiao et al. [28].
Figure 6The neoplastic cells form ill-defined nests with a diffuse growth pattern. Some tumor cells have clear cytoplasm. The surface mucosa is not involved by the underlying tumor (Case 1) (hematoxylin-eosin, original magnification ×200) Xiao et al. [28].
Figure 7The nuclei of the tumor cells are relatively uniform with finely granular chromatin, inconspicuous nucleoli, and rare mitosis (Case 1) (hematoxylin-eosin, original magnification ×400) Xiao et al. [28].
Figure 9The cytologically bland neoplastic cells are arranged in a diffuse pattern of relatively ill-defined and variably sized nests (Case 2) (hematoxylin-eosin, original magnification ×600) Xiao et al. [28].
Figure 8The neoplastic cells are strongly immunoreactive for p63 (Case 1) (p63, original magnification ×200) Xiao et al. [28].
Figure 10The neoplastic cells are strongly immunoreactive for p63 (Case 2) (p63, original magnification ×400) Xiao et al. [28].
Figure 4von Brunn nests in comparison with nested variant of urothelial carcinoma showing regularly spaced urothelial nests with a relatively flat base (hematoxylin-eosin, original magnification ×200). Nested variant of urothelial carcinoma taken from Dhall et al. [2]. The figures have been reproduced with the permission of the editor in chief of Archives of Pathology and Laboratory Medicine on behalf of the editorial board of the journal.